Affimed signs innate cell antibody engager deal with Genentech
Affimed NV and Roche’s Genentech Inc. agreed to discover and conduct early- and late-stage research on innate immune cell--natural killer (NK) cell and T-cell--immunotherapies against certain Genentech-selected targets for various solid and hematological tumors. Genentech will take over clinical development and hold exclusive global commercialization rights; it is also responsible for related costs.
- Large Molecule
- Includes Contract
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com